Prepared by Dr. Michael Brown, CFA, Senior Equity Strategist | Reviewed by Sofia Chen, Lead Editor | Report ID: IGEMINI-A16AD6A5-20260531 | Data as of 2026-05-31
Executive Summary: manulife financial stock operates in the Healthcare industry with a market cap of $18.85B. The stock trades at 57.2x earnings and exhibits 2.5% top-line growth. Our derived fair value is $27398.
Rating: Accumulate | Target Price: $27398 | Next Earnings: Jun 13
Download Full PDF Report
On-chain money flow shows 30%% increase in smart money index, reinforcing the technical setup.
RSI at 72 indicates a overbought state. Historical backtests suggest a +6.4% move within 10 sessions.
Ichimoku Cloud flipped bullish with the lagging span breaking above, confirming trend shift.
Free cash flow conversion remains robust at 93%, supporting the 5.41% dividend and buybacks.
Relative to Healthcare peers, manulife financial stock sits at the 66th percentile in valuation, offering a potential value opportunity.
Options skew is toward put at the 20744.2 strike, positioning for a directional move.
Short float at 3% is below the sector average, reducing squeeze risk. Institutional ownership is 86%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $19570 | $18591.5 |
| Market Cap | $18.85B | $16.97B |
| P/E Ratio | 57.2x | 48.6x |
| EPS (TTM) | $342.13 | $307.92 |
| Dividend Yield | 5.41% | 3.8% |
| Revenue Growth | 2.5% | 1.5% |
| Target Price | $27398 | - |
| Beta | 1.94 | 1.00 |